Cinzia Parolini1. 1. Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, via Balzaretti, 9, 20133, Milan, Italy. cinzia.parolini@unimi.it.
Abstract
BACKGROUND: Despite advances in the development of lipid-lowering therapies, clinical trials have shown that a significant residual risk of cardiovascular disease persists. Specifically, new drugs are needed for non-responding or statin-intolerant subjects or patients considered at very high risk for cardiovascular events even though are already on treatment with the best standard of care. RESULTS AND CONCLUSIONS: Besides, genetic and epidemiological studies and Mendelian randomization analyses have strengthened the linear correlation between the concentration of low-density lipoprotein cholesterol (LDL-C) and the incidence of cardiovascular events and highlighted various novel therapeutic targets. This review describes the novel strategies to reduce the levels of LDL-C, non-HDL-C, triglyceride, apolipoprotein B, and Lp(a), focusing on those developed using biotechnology-based strategies.
BACKGROUND: Despite advances in the development of lipid-lowering therapies, clinical trials have shown that a significant residual risk of cardiovascular disease persists. Specifically, new drugs are needed for non-responding or statin-intolerant subjects or patients considered at very high risk for cardiovascular events even though are already on treatment with the best standard of care. RESULTS AND CONCLUSIONS: Besides, genetic and epidemiological studies and Mendelian randomization analyses have strengthened the linear correlation between the concentration of low-density lipoprotein cholesterol (LDL-C) and the incidence of cardiovascular events and highlighted various novel therapeutic targets. This review describes the novel strategies to reduce the levels of LDL-C, non-HDL-C, triglyceride, apolipoprotein B, and Lp(a), focusing on those developed using biotechnology-based strategies.
Authors: Thomas J Povsic; Rob Scott; Kenneth W Mahaffey; Robert Blaustein; Jay M Edelberg; Martin P Lefkowitz; Scott D Solomon; Jonathan C Fox; Kevin E Healy; Aarif Y Khakoo; Douglas W Losordo; Fady I Malik; Brett P Monia; Rusty L Montgomery; Jeffrey Riesmeyer; Gregory G Schwartz; Steven L Zelenkofske; Joseph C Wu; Scott M Wasserman; Matthew T Roe Journal: Cardiovasc Drugs Ther Date: 2017-08 Impact factor: 3.727
Authors: Brian A Ference; Wonsuk Yoo; Issa Alesh; Nitin Mahajan; Karolina K Mirowska; Abhishek Mewada; Joel Kahn; Luis Afonso; Kim Allan Williams; John M Flack Journal: J Am Coll Cardiol Date: 2012-10-17 Impact factor: 24.094
Authors: Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh Journal: J Lipid Res Date: 2012-07-17 Impact factor: 5.922
Authors: Stephen Sidney; Charles P Quesenberry; Marc G Jaffe; Michael Sorel; Mai N Nguyen-Huynh; Lawrence H Kushi; Alan S Go; Jamal S Rana Journal: JAMA Cardiol Date: 2016-08-01 Impact factor: 14.676
Authors: Ann Marie Navar-Boggan; Eric D Peterson; Ralph B D'Agostino; Benjamin Neely; Allan D Sniderman; Michael J Pencina Journal: Circulation Date: 2015-01-26 Impact factor: 29.690
Authors: Om P Ganda; Deepak L Bhatt; R Preston Mason; Michael Miller; William E Boden Journal: J Am Coll Cardiol Date: 2018-06-20 Impact factor: 24.094
Authors: Brian A Ference; Henry N Ginsberg; Ian Graham; Kausik K Ray; Chris J Packard; Eric Bruckert; Robert A Hegele; Ronald M Krauss; Frederick J Raal; Heribert Schunkert; Gerald F Watts; Jan Borén; Sergio Fazio; Jay D Horton; Luis Masana; Stephen J Nicholls; Børge G Nordestgaard; Bart van de Sluis; Marja-Riitta Taskinen; Lale Tokgözoglu; Ulf Landmesser; Ulrich Laufs; Olov Wiklund; Jane K Stock; M John Chapman; Alberico L Catapano Journal: Eur Heart J Date: 2017-08-21 Impact factor: 29.983
Authors: Imelda Ontoria-Oviedo; Elena Amaro-Prellezo; Delia Castellano; Elena Venegas-Venegas; Fernando González-Santos; Amparo Ruiz-Saurí; Beatriz Pelacho; Felipe Prósper; María Dolores Pérez Del Caz; Pilar Sepúlveda Journal: Int J Mol Sci Date: 2022-08-31 Impact factor: 6.208